Thomas Steyer’s Cidara Therapeutics CDTX Stock Holding History

Thomas Steyer’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-382,800	Closed	-$84.6M	–	178
2025 Q4	$84.6M	Sell	382,800 -125,200	-25%	-$20.2M	0.37%	49
2025 Q3	$48.6M	Buy	508,000 +308,000	+154%	+$19.7M	0.2%	56
2025 Q2	$9.74M	Buy	+200,000	New	+$4.81M	0.04%	82

Thomas Steyer's CDTX Position: Q1 2026 in Review

Thomas Steyer sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 382,800 shares — an estimated $84.6M sold.

Thomas Steyer first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $84.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Thomas Steyer reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Thomas Steyer sold 382,800 Cidara Therapeutics shares in Q1 2026, an estimated $84.6M.
Thomas Steyer first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Thomas Steyer's Cidara Therapeutics position peaked at $84.6M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.